Patents by Inventor Viktor S. Goldmakher

Viktor S. Goldmakher has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Folate Receptor 1 Antibodies and Immunoconjugates and Uses Thereof
    Publication number: 20210032327
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to human folate receptor 1 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.
    Type: Application
    Filed: July 21, 2020
    Publication date: February 4, 2021
    Applicant: ImmunoGen, Inc.
    Inventors: Olga AB, Daniel Tavares, Lingyun Rui, Gillian Payne, Viktor S. Goldmakher
  • Folate receptor 1 antibodies and immunoconjugates and uses thereof
    Patent number: 10752683
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to human folate receptor 1 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.
    Type: Grant
    Filed: April 15, 2019
    Date of Patent: August 25, 2020
    Assignee: ImmunoGen, Inc.
    Inventors: Olga Ab, Daniel Tavares, Lingyun Rui, Gillian Payne, Viktor S. Goldmakher
  • Folate Receptor 1 Antibodies and Immunoconjugates and Uses Thereof
    Publication number: 20190345248
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to human folate receptor 1 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.
    Type: Application
    Filed: April 15, 2019
    Publication date: November 14, 2019
    Applicant: ImmunoGen, Inc.
    Inventors: Olga AB, Daniel TAVARES, Lingyun RUI, Gillian PAYNE, Viktor S. GOLDMAKHER
  • Folate receptor 1 antibodies and immunoconjugates and uses thereof
    Patent number: 10301385
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to human folate receptor 1 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.
    Type: Grant
    Filed: May 1, 2017
    Date of Patent: May 28, 2019
    Assignee: ImmunoGen, Inc.
    Inventors: Olga Ab, Daniel Tavares, Lingyun Rui, Gillian Payne, Viktor S. Goldmakher
  • Folate Receptor 1 Antibodies and Immunoconjugates and Uses Thereof
    Publication number: 20170327575
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to human folate receptor 1 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.
    Type: Application
    Filed: May 1, 2017
    Publication date: November 16, 2017
    Applicant: ImmunoGen, Inc.
    Inventors: Olga AB, Daniel TAVARES, Lingyun RUI, Gillian PAYNE, Viktor S. GOLDMAKHER
  • Folate receptor 1 antibodies and immunoconjugates and uses thereof
    Patent number: 9670279
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to human folate receptor 1 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: June 6, 2017
    Assignee: ImmunoGen, Inc.
    Inventors: Olga Ab, Daniel Tavares, Lingyun Rui, Gillian Payne, Viktor S. Goldmakher
  • Folate receptor 1 antibodies and immunoconjugates and uses thereof
    Patent number: 9670278
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to human folate receptor 1 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: June 6, 2017
    Assignee: ImmunoGen, Inc.
    Inventors: Olga Ab, Daniel Tavares, Lingyun Rui, Gillian Payne, Viktor S. Goldmakher
  • Folate receptor 1 antibodies and immunoconjugates and uses thereof
    Patent number: 9670280
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to human folate receptor 1 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.
    Type: Grant
    Filed: December 15, 2015
    Date of Patent: June 6, 2017
    Assignee: ImmunoGen, Inc.
    Inventors: Olga Ab, Daniel Tavares, Lingyun Rui, Gillian Payne, Viktor S. Goldmakher
  • Folate receptor 1 antibodies and immunoconjugates and uses thereof
    Patent number: 9657100
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to human folate receptor 1 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.
    Type: Grant
    Filed: August 5, 2015
    Date of Patent: May 23, 2017
    Assignee: ImmunoGen, Inc.
    Inventors: Olga Ab, Daniel Tavares, Lingyun Rui, Gillian Payne, Viktor S. Goldmakher
  • Folate receptor 1 antibodies and immunoconjugates and uses thereof
    Patent number: 9598490
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to human folate receptor 1 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.
    Type: Grant
    Filed: December 15, 2015
    Date of Patent: March 21, 2017
    Assignee: ImmunoGen, Inc.
    Inventors: Olga Ab, Daniel Tavares, Lingyun Rui, Gillian Payne, Viktor S. Goldmakher
  • Folate Receptor 1 Antibodies and Immunoconjugates and Uses Thereof
    Publication number: 20160096887
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to human folate receptor 1 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.
    Type: Application
    Filed: December 15, 2015
    Publication date: April 7, 2016
    Applicant: ImmunoGen, Inc.
    Inventors: Olga AB, Daniel Tavares, Lingyun Rui, Gillian Payne, Viktor S. Goldmakher
  • Folate Receptor 1 Antibodies and Immunoconjugates and Uses Thereof
    Publication number: 20160096888
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to human folate receptor 1 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.
    Type: Application
    Filed: December 15, 2015
    Publication date: April 7, 2016
    Applicant: ImmunoGen, Inc.
    Inventors: Olga AB, Daniel Tavares, Lingyun Rui, Gillian Payne, Viktor S. Goldmakher
  • Folate Receptor 1 Antibodies and Immunoconjugates and Uses Thereof
    Publication number: 20160083471
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to human folate receptor 1 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.
    Type: Application
    Filed: November 19, 2015
    Publication date: March 24, 2016
    Applicant: ImmunoGen, Inc.
    Inventors: Olga AB, Daniel Tavares, Lingyun Rui, Gillian Payne, Viktor S. Goldmakher
  • Folate Receptor 1 Antibodies and Immunoconjugates and Uses Thereof
    Publication number: 20160075781
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to human folate receptor 1 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.
    Type: Application
    Filed: November 25, 2015
    Publication date: March 17, 2016
    Applicant: ImmunoGen, Inc.
    Inventors: Olga AB, Daniel Tavares, Lingyun Rui, Gillian Payne, Viktor S. Goldmakher
  • Folate Receptor 1 Antibodies and Immunoconjugates and Uses Thereof
    Publication number: 20160060339
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to human folate receptor 1 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.
    Type: Application
    Filed: August 5, 2015
    Publication date: March 3, 2016
    Applicant: ImmunoGen, Inc.
    Inventors: Olga AB, Daniel Tavares, Lingyun Rui, Gillian Payne, Viktor S. Goldmakher
  • Folate receptor 1 antibodies and immunoconjugates and uses thereof
    Patent number: 9133275
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to human folate receptor 1 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: September 15, 2015
    Assignee: ImmunoGen, Inc.
    Inventors: Olga Ab, Daniel Tavares, Lingyun Rui, Gillian Payne, Viktor S. Goldmakher
  • IMMUNOCONJUGATES TARGETING SYNDECAN-1 EXPRESSING CELLS AND USE THEREOF
    Publication number: 20150010585
    Abstract: Immunoconjugates comprising a targeting agent selectively targeting cell-surface expressed syndecan-1 and at least one effector molecule as well as in vitro and in vivo methods of using those immunocomjugates are disclosed. The effector molecule may have, in its native form, high non-selective cytotoxicity, but substantially no non-selective cytotoxicity when part of said immunoconjugate. Targeting agents include the antibody B-B4 as well as other agents that bind cell-surface expressed syndecan-1.
    Type: Application
    Filed: July 10, 2014
    Publication date: January 8, 2015
    Inventor: Viktor S. Goldmakher
  • Immunoconjugates targeting syndecan-1 expressing cells and use thereof
    Patent number: 8840898
    Abstract: Immunoconjugates comprising a targeting agent selectively targeting cell-surface expressed syndecan-1 and at least one effector molecule as well as in vitro and in vivo methods of using those immunocomjugates are disclosed. The effector molecule may have, in its native form, high non-selective cytotoxicity, but substantially no non-selective cytotoxicity when part of said immunoconjugate. Targeting agents include the antibody B-B4 as well as other agents that bind cell-surface expressed syndecan-1.
    Type: Grant
    Filed: April 16, 2007
    Date of Patent: September 23, 2014
    Assignees: Biotest AG, ImmunoGen, Inc.
    Inventor: Viktor S. Goldmakher
  • Folate receptor 1 antibodies and immunoconjugates and uses thereof
    Patent number: 8557966
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to human folate receptor 1 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.
    Type: Grant
    Filed: February 24, 2011
    Date of Patent: October 15, 2013
    Assignee: ImmunoGen, Inc.
    Inventors: Olga Ab, Daniel Tavares, Lingyun Rui, Gillian Payne, Viktor S. Goldmakher
  • Elimination of heterogeneous or mixed cell population in tumors
    Patent number: 8388960
    Abstract: Methods of killing or inhibiting tumors comprising of heterogeneous or mixed cell populations is described. The killing or inhibition of tumors is achieved by selectively targeting a unique ligand suspected of being expressed on a particular cell population to also kill a cell population lacking the unique ligand. These conjugates have therapeutic use as they are delivered to a specific cell population to kill these cells and the cytotoxic drug is released to kill non-targeted cells, thereby eliminating the tumor.
    Type: Grant
    Filed: September 9, 2011
    Date of Patent: March 5, 2013
    Assignee: Immunogen Inc.
    Inventors: Viktor S. Goldmakher, Robert J. Lutz, Ravi V. J. Chari, Yelena V. Kovtun, John M. Lambert, Rita Steeves, Hans K. Erickson, Wayne C. Widdison